Ocrevus (ocrelizumab) is a breakthrough treatment for Multiple Sclerosis (MS). Billed under HCPCS code J2350, it requires complex IV infusion administration coding and strict diagnosis tracking.
Calculating Units for Ocrevus (J2350)
The code J2350 is defined as "Injection, ocrelizumab, 1 mg".
A standard maintenance dose of Ocrevus is 600 mg, administered every 6 months. Therefore, you will bill exactly 600 units on the claim.
| Drug | Code | Administered Dosage | Billing Units |
|---|---|---|---|
| Ocrevus | J2350 | 600 mg | 600 |
Covered Diagnoses (Medical Necessity)
Ocrevus is FDA-approved and covered for relapsing or primary progressive forms of multiple sclerosis. Your claim must include a valid ICD-10 code such as:
- G35 - Multiple sclerosis
IV Infusion Administration (CPT 96413)
Because Ocrevus is a complex biologic infusion, it is typically billed using chemotherapy/complex biologic administration codes rather than standard therapeutic infusion codes. You will generally bill 96413 (Chemotherapy administration, IV, up to 1 hour) and 96415 for each additional hour.
Always verify your specific payer's preference and run a dual-code NCCI check before submitting.